Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06467500RecruitingPhase 2
Cadonilimab plus chemo for lung cancer after immunotherapy
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
YichangAges 18–75 - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT06449313RecruitingPhase 2
Immunotherapy before lung cancer surgery for stage 3 disease
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT07412262RecruitingPhase 2
Study of chidamide and ivonescimab for advanced lung cancer after immunotherapy resistance
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
Guangzhou, GuangdongAges 18 years+ - NCT01639508RecruitingPhase 2
Cabozantinib for lung cancer with specific gene changes
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
Basking Ridge, New JerseyAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Daphne, AlabamaAges 18 minutes+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Jonesboro, ArkansasAges 18 years+ - NCT05339568Recruiting
Smartphone support program for people with advanced lung cancer
This trial tests a “whole process follow-up” care plan, using a smartphone, to support people with non-small cell lung cancer from diagnosis through treatment and follow-up. It may help you manage care steps more smoothly if you’re not a candidate for curative (radical) treatment or don’t want surgery.
Jinan, ShandongAges 18 years+ - NCT05830500RecruitingPhase 4
Anlotinib for advanced medullary thyroid cancer
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
Hefei, AnhuiAges 18–75 - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT05060796RecruitingEarly Phase 1
CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
GuangzhouAges 18–75 - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,520 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.